AR115790A1 - Apirasas solubilizadas, métodos y usos - Google Patents

Apirasas solubilizadas, métodos y usos

Info

Publication number
AR115790A1
AR115790A1 ARP190102009A ARP190102009A AR115790A1 AR 115790 A1 AR115790 A1 AR 115790A1 AR P190102009 A ARP190102009 A AR P190102009A AR P190102009 A ARP190102009 A AR P190102009A AR 115790 A1 AR115790 A1 AR 115790A1
Authority
AR
Argentina
Prior art keywords
solubilized
methods
apirases
concerned
preventing
Prior art date
Application number
ARP190102009A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR115790A1 publication Critical patent/AR115790A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere al diseño y uso terapéutico de polipéptidos de apirasa solubilizados, composiciones farmacéuticas, usos terapéuticos y métodos útiles para prevenir y tratar el daño tisular.
ARP190102009A 2018-07-18 2019-07-16 Apirasas solubilizadas, métodos y usos AR115790A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18184269 2018-07-18

Publications (1)

Publication Number Publication Date
AR115790A1 true AR115790A1 (es) 2021-02-24

Family

ID=62985993

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102009A AR115790A1 (es) 2018-07-18 2019-07-16 Apirasas solubilizadas, métodos y usos

Country Status (26)

Country Link
US (1) US20220356455A1 (es)
EP (1) EP3824079A1 (es)
JP (2) JP7425784B2 (es)
KR (1) KR20210035806A (es)
CN (1) CN112424346A (es)
AR (1) AR115790A1 (es)
AU (1) AU2019306821B2 (es)
BR (1) BR112021000586A2 (es)
CA (1) CA3103684A1 (es)
CL (1) CL2021000129A1 (es)
CO (1) CO2021000210A2 (es)
CR (1) CR20210021A (es)
CU (1) CU20210008A7 (es)
EA (1) EA202190057A1 (es)
EC (1) ECSP21002804A (es)
IL (1) IL280191A (es)
JO (1) JOP20210008A1 (es)
MA (1) MA53177A (es)
MX (1) MX2021000542A (es)
PE (1) PE20210185A1 (es)
PH (1) PH12021550122A1 (es)
SG (1) SG11202011776RA (es)
TW (1) TW202016299A (es)
UY (1) UY38299A (es)
WO (1) WO2020016804A1 (es)
ZA (1) ZA202007187B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243173A1 (en) * 2020-05-28 2021-12-02 Charm Sciences, Inc. Methods and assemblies for sample analysis
WO2024023746A1 (en) 2022-07-29 2024-02-01 Novartis Ag Improved production of cd39 variants
TW202404627A (zh) 2022-07-29 2024-02-01 瑞士商諾華公司 使用cd39、重組cd39用於急性器官損傷的治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6425699A (en) 1998-10-16 2000-05-08 Cornell Research Foundation Inc. Methods of inhibiting platelet activation and recruitment
US20020002277A1 (en) * 1998-10-16 2002-01-03 Maliszewski Charles Richard Inhibitors of platelet activation and recruitment
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
WO2006096989A2 (en) 2005-03-17 2006-09-21 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression
WO2011088231A1 (en) * 2010-01-13 2011-07-21 Apt Therapeutics, Inc. Apyrase therapy for bleeding conditions
DK3083677T3 (da) 2013-12-20 2019-11-25 Novartis Ag Hidtil ukendte eukaryote celler og fremgangsmåder til rekombinant ekspression af et produkt af interesse
RU2720525C2 (ru) 2013-12-20 2020-04-30 Новартис Аг Новые эукариотические клетки и способы их получения для рекомбинантной экспрессии представляющего интерес продукта

Also Published As

Publication number Publication date
CA3103684A1 (en) 2020-01-23
AU2019306821A1 (en) 2020-12-24
CO2021000210A2 (es) 2021-01-18
JP2024023297A (ja) 2024-02-21
BR112021000586A2 (pt) 2021-04-06
KR20210035806A (ko) 2021-04-01
CU20210008A7 (es) 2021-08-06
JP7425784B2 (ja) 2024-01-31
US20220356455A1 (en) 2022-11-10
PE20210185A1 (es) 2021-02-02
EP3824079A1 (en) 2021-05-26
SG11202011776RA (en) 2021-02-25
WO2020016804A1 (en) 2020-01-23
CR20210021A (es) 2021-03-23
CL2021000129A1 (es) 2021-08-20
MA53177A (fr) 2021-05-26
ZA202007187B (en) 2022-06-29
PH12021550122A1 (en) 2021-09-27
CN112424346A (zh) 2021-02-26
JOP20210008A1 (ar) 2021-01-12
JP2021529550A (ja) 2021-11-04
MX2021000542A (es) 2021-03-29
ECSP21002804A (es) 2021-04-29
TW202016299A (zh) 2020-05-01
UY38299A (es) 2020-02-28
AU2019306821B2 (en) 2022-09-29
EA202190057A1 (ru) 2021-08-24
IL280191A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
UY37831A (es) Nuevos derivados de quinolina
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CO2018008449A2 (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CO2022000481A2 (es) Inhibidores de enzimas
CO2018008450A2 (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2016002482A1 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2.
CL2018001911A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CL2021000529A1 (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
BR112012015386B8 (pt) composição oftálmica tópica
CO2022000270A2 (es) Inhibidores de enzimas
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
BR112018003455A2 (pt) composição ou composição farmacêutica e uso da composição
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.